Table 2. Changes in Glycemia according to SU and Concurrent Antidiabetic Medications.
| Variable | (A) Baseline | (B) After SU-free period (4.8±1.5 mo) | (C) After SU re-use (2.4±0.8 mo) | Post hoc analysis by Tukey's multiple comparison test, if repeated measures ANOVA P<0.05 | ||
|---|---|---|---|---|---|---|
| P for A vs. B | P for B vs. C | P for A vs. C | ||||
| FPG, mg/dL | 129.2±20.2 | 206.0±47.5 | 142.4±23.6 | <0.0001 | <0.0001 | NS |
| Glycated hemoglobin, % | 6.7±0.4 | 8.8±0.8 | 7.4±0.7 | <0.0001 | <0.0001 | <0.001 |
| SU as glimepiride-equivalent, mg/daya | 1.0±0.6 | 0 | 1.3±0.8 | <0.001 | <0.001 | NS |
| Concurrent antidiabetic agents, mg/day | ||||||
| Metformin | 1,390±590 (n=17) | 1,400±510 (n=19) | 1,290±530 (n=18) | NA | NA | NA |
| Pioglitazone | 15±0 (n=4) | 14±3 (n=7) | 15±0 (n=4) | NA | NA | NA |
| DPP-4 inhibitors | 100±0 (n=5)b | 94±17 (n=9)b,c | 90±22 (n=5)b | <0.05 | <0.05 | NS |
Values are expressed as mean±SD.
SU, sulfonylurea; ANOVA, analysis of variance; FPG, fasting plasma glucose; NS, not significant; NA, not applicable; DPP-4, dipeptidyl peptidase-4.
aConversion factors in Table 1; bSitagliptin or vildagliptin; cThere were 2 cases of saxagliptin, and the 5 mg of saxagliptin was regarded as 100 mg of sitagliptin.